Anal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Anal Cancer Pipeline Drugs Market Report Overview
Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.
The Anal Cancer – drugs in development research report provides a comprehensive overview on the therapeutics under development for Anal cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal cancer and features dormant and discontinued projects.
| Key Targets | Programmed Cell Death Protein 1, Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Tumor Necrosis Factor Receptor Superfamily Member 9, Cells Expressing Human Papillomavirus Protein E7, Cells Expressing Human Papillomavirus Type 16 Protein E6, Epidermal Growth Factor Receptor, and Interleukin 12 |
| Key Mechanisms of action | Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Cytotoxic To Cells Expressing Human Papillomavirus Type 16 Protein E6, Epidermal Growth Factor Receptor Antagonist, Interleukin 12 Receptor Agonist, and Interleukin 15 Receptor Subunit Alpha Agonist |
| Key Routes of Administration | Intravenous, Subcutaneous, Intramuscular, Oral, Intratumor, Parenteral, Topical, Intralesional, Intraperitoneal, and Intravenous Drip |
| Key molecule types | Monoclonal Antibody, Small Molecule, Cell Therapy, Fusion Protein, Subunit Vaccine, Gene-Modified Cell Therapy, Recombinant Vector Vaccine, Recombinant Protein, and Oncolytic Virus |
| Major companies | Incyte Corp, Merck & Co Inc, F. Hoffmann-La Roche Ltd, Merck KGaA, AstraZeneca Plc, Eli Lilly and Co, Hookipa Pharma Inc, Molecular Partners AG, Privo Technologies Inc, Rubius Therapeutics Inc, SQZ Biotechnologies Co, TScan Therapeutics Inc, Xencor Inc, and Antiva Biosciences Inc |
Key Targets in the Anal Cancer Pipeline Drugs Market
The key targets in the Anal Cancer pipeline drugs market are Programmed Cell Death Protein 1, Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Tumor Necrosis Factor Receptor Superfamily Member 9, Cells Expressing Human Papillomavirus Protein E7, Cells Expressing Human Papillomavirus Type 16 Protein E6, Epidermal Growth Factor Receptor, and Interleukin 12. Programmed Cell Death Protein 1 has the highest number of pipeline products.
Anal Cancer Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Anal Cancer Pipeline Drugs Market
The key mechanisms of action in the Anal Cancer pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Cytotoxic To Cells Expressing Human Papillomavirus Type 16 Protein E6, Epidermal Growth Factor Receptor Antagonist, Interleukin 12 Receptor Agonist, Interleukin 15 Receptor Subunit Alpha Agonist, and Lymphocyte Activation Gene 3 Protein Inhibitor.
Anal Cancer Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Anal Cancer Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Anal Cancer pipeline drugs market are Intravenous, Subcutaneous, Intramuscular, Oral, Intratumor, Parenteral, Topical, Intralesional, Intraperitoneal, and Intravenous Drip.
Anal Cancer Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Anal Cancer Pipeline Drugs Market
Monoclonal Antibody has the highest number of pipeline products in the Anal Cancer pipeline drugs market followed by Small Molecule, Cell Therapy, Fusion Protein, Subunit Vaccine, Gene-Modified Cell Therapy, Recombinant Vector Vaccine, Recombinant Protein, Oncolytic Virus, and Vaccine.
Anal Cancer Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Anal Cancer Pipeline Drugs Market
The major companies in the Anal Cancer pipeline drugs market are Incyte Corp, Merck & Co Inc, F. Hoffmann-La Roche Ltd, Merck KGaA, AstraZeneca Plc, Eli Lilly and Co, Hookipa Pharma Inc, Molecular Partners AG, Privo Technologies Inc, Rubius Therapeutics Inc, SQZ Biotechnologies Co, TScan Therapeutics Inc, Xencor Inc, and Antiva Biosciences Inc.
Incyte Corp: Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. Jakafi is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company’s pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
Anal Cancer Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer
- The pipeline guide reviews pipeline therapeutics for Anal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
- The pipeline guide reviews key companies involved in Anal Cancer therapeutics and enlists all their major and minor projects
- The pipeline guide evaluates Anal Cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects
- The pipeline guide reviews the latest news related to pipeline therapeutics for Anal Cancer
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage
- Find and recognize significant and varied types of therapeutics under development for Anal Cancer
- Classify potential new clients or partners in the target demographic
- Develop tactical initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics
- Formulate corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline
AstraZeneca Plc
Beijing Corregene Biotechnology Co Ltd
Beijing Kangle Guardian Biotechnology Co Ltd
Bicara Therapeutics Inc
Biomimetix JV LLC
Bristol-Myers Squibb Co
Cue Biopharma Inc
CytomX Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
EpimAb Biotherapeutics Inc
eTheRNA Immunotherapies NV
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corp
Genexine Inc
Genocea Biosciences Inc
Gilead Sciences Inc
Guangzhou BeBetter Medicine Technology Co Ltd
HaloVax
Hookipa Pharma Inc
IMV Inc
Incyte Corp
Invectys SA
ISA Pharmaceuticals BV
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Molecular Partners AG
Nektar Therapeutics
Novartis AG
Oncolytics Biotech Inc
Onconova Therapeutics Inc
Oncorus Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Precigen Inc
Privo Technologies Inc
Repertoire Immune Medicines Inc
Rubius Therapeutics Inc
Sanofi
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Zerun Biotechnology Co Ltd
Shattuck Labs Inc
SinoCelltech Group Ltd
SOTIO Biotech AS
SQZ Biotechnologies Co
Statera Biopharma Inc
Transgene SA
Treadwell Therapeutics Inc
TScan Therapeutics Inc
Turnstone Biologics Inc
Virion Therapeutics LLC
Xencor Inc
Y-Biologics Inc
Zymeworks Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Anal Cancer pipeline drugs market?
In the Anal Cancer pipeline drugs market the key targets are Programmed Cell Death Protein 1, Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Tumor Necrosis Factor Receptor Superfamily Member 9, Cells Expressing Human Papillomavirus Protein E7, Cells Expressing Human Papillomavirus Type 16 Protein E6, Epidermal Growth Factor Receptor, and Interleukin 12.
-
What are the key mechanisms of action in the Anal Cancer pipeline drugs market?
The key mechanisms of action in the Anal Cancer pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Cytotoxic To Cells Expressing Human Papillomavirus Type 16 Protein E6, Epidermal Growth Factor Receptor Antagonist, Interleukin 12 Receptor Agonist, and Interleukin 15 Receptor Subunit Alpha Agonist.
-
What are the key routes of administration in the Anal Cancer pipeline drugs market?
The key routes of administration in the Anal Cancer pipeline drugs market are Intravenous, Subcutaneous, Intramuscular, Oral, Intratumor, Parenteral, Topical, Intralesional, Intraperitoneal, and Intravenous Drip. Intravenous has the highest number of pipeline products.
-
What are the key molecule types in the Anal Cancer pipeline drugs market?
The key molecule types in the Anal Cancer pipeline drugs market are Monoclonal Antibody, Small Molecule, Cell Therapy, Fusion Protein, Subunit Vaccine, Gene-Modified Cell Therapy, Recombinant Vector Vaccine, Recombinant Protein, and Oncolytic Virus.
-
What are the major companies in the Anal Cancer pipeline drugs market?
In the Anal Cancer pipeline drugs market the major companies are Incyte Corp, Merck & Co Inc, F. Hoffmann-La Roche Ltd, Merck KGaA, AstraZeneca Plc, Eli Lilly and Co, Hookipa Pharma Inc, Molecular Partners AG, Privo Technologies Inc, Rubius Therapeutics Inc, SQZ Biotechnologies Co, TScan Therapeutics Inc, Xencor Inc, and Antiva Biosciences Inc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Oncology reports